Begin patient enrollment in expanded Phase 2 clinical trial of stenoparib
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 7 Feb 2025
- Due
- 30 Jun 2025
- Delivered
- 2 Jun 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Patient enrollment is expected to begin in the first half of 2025, subject to final protocol review by regulatory authorities.”
What we found
Evidence strength A What the grades mean
Allarity announced on June 2, 2025 that the first patient was enrolled in the expanded Phase 2 stenoparib trial, within the first-half-2025 target.
-
A Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol (8-K exhibit) SEC filing announcing IRB approval and imminent enrollment start
-
B Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib Confirms first patient enrolled in early June 2025, several patients dosed
-
B Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer Announces first patient enrolled in new Phase 2 stenoparib protocol
Checked 16 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Begin
- Language
- Expected (“expects”, “plans”)
- Conditional
- Yes
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Allarity Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-ALLR-000391 · Corrections policy